Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Hologic announced the long-term, five-year results from the ASBS MammoSite(R) Breast Brachytherapy Registry Trial  while showcasing the MammoSite ML (multi-lumen) system at the 2010 ASTRO Meeting

Hologic , Inc. (Hologic or the Company) (HOLX 16.12, +0.09, +0.56%) , a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women,  announced the long-term, five-year results from the American Society of Breast Surgeons (ASBS) MammoSite(R) Breast Brachytherapy Registry Trial (ASBS Registry) while showcasing the MammoSite ML (multi-lumen) system at the 52nd ASTRO ( American Society for Radiation Oncology ) Annual Meeting in San Diego October 31 through November 4, 2010. The ASBS Registry Trial represents the largest compilation of MammoSite patients to date and demonstrates promising results for breast cancer patients. The MammoSite system is the only breast brachytherapy balloon with five-year efficacy data. Of the 1,449 patients (1,440 treated) with early-stage breast cancer, 37 patients had an ipsilateral breast tumor recurrence (IBTR), for a five-year actuarial rate of 3.80 percent. A subset analysis of the first 400 consecutive cases had a median follow-up of 60.5 months and demonstrated a five-year actuarial rate of IBTR of 3.04 percent.

According to Frank Vicini, M.D., principal investigator of the study, "The data are promising and add further clinical support for the use of accelerated partial breast irradiation in appropriate patients."

Carter Houghton, Vice President and General Manager of Hologic 's Interventional Breast Solutions business, added, "The five-year ASBS Registry findings are a significant milestone for the MammoSite technology. Good local cancer control rates and cosmetic results are critical outcomes in breast cancer therapy. We look forward to expanding the utilization of accelerated partial breast irradiation by breast cancer patients that may have previously been disqualified for treatment."

The study concludes that treatment efficacy, cosmesis, and toxicity five years after treatment with APBI using the MammoSite device are good and similar to those reported with other forms of APBI with similar follow-up.*

*Vicini F, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial in patients treated with accelerated partial breast irradiation. International Journal of Radiation Oncology, Biology, Physics

Source: Hologic , Inc.